6-(SUBSTITUTED METHYLENE)PENEMS, POTENT BROAD-SPECTRUM INHIBITORS OF BACTERIAL BETA-LACTAMASE .3. STRUCTURE-ACTIVITY-RELATIONSHIPS OF THE 5-MEMBERED HETEROCYCLIC-DERIVATIVES
被引:40
作者:
BENNETT, I
论文数: 0引用数: 0
h-index: 0
机构:SmithKline Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Brockham Park, Betchworth, Surrey
BENNETT, I
BROOM, NJP
论文数: 0引用数: 0
h-index: 0
机构:SmithKline Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Brockham Park, Betchworth, Surrey
BROOM, NJP
BRUTON, G
论文数: 0引用数: 0
h-index: 0
机构:SmithKline Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Brockham Park, Betchworth, Surrey
BRUTON, G
CALVERT, S
论文数: 0引用数: 0
h-index: 0
机构:SmithKline Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Brockham Park, Betchworth, Surrey
CALVERT, S
CLARKE, BP
论文数: 0引用数: 0
h-index: 0
机构:SmithKline Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Brockham Park, Betchworth, Surrey
CLARKE, BP
COLEMAN, K
论文数: 0引用数: 0
h-index: 0
机构:SmithKline Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Brockham Park, Betchworth, Surrey
COLEMAN, K
EDMONDSON, R
论文数: 0引用数: 0
h-index: 0
机构:SmithKline Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Brockham Park, Betchworth, Surrey
EDMONDSON, R
EDWARDS, P
论文数: 0引用数: 0
h-index: 0
机构:SmithKline Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Brockham Park, Betchworth, Surrey
EDWARDS, P
JONES, D
论文数: 0引用数: 0
h-index: 0
机构:SmithKline Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Brockham Park, Betchworth, Surrey
JONES, D
OSBORNE, NF
论文数: 0引用数: 0
h-index: 0
机构:SmithKline Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Brockham Park, Betchworth, Surrey
OSBORNE, NF
WALKER, G
论文数: 0引用数: 0
h-index: 0
机构:SmithKline Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Brockham Park, Betchworth, Surrey
WALKER, G
机构:
[1] SmithKline Beecham Pharmaceuticals, Chemotherapeutic Research Centre, Brockham Park, Betchworth, Surrey
Sodium (5RS)-Z-6-(heterocyclylmethylene)penem-3-carboxylates (2) are a series of extremely potent inhibitors of bacterial beta-lactamases. A variety of 5-membered heteroaromatic derivatives have been prepared and structure-activity studies reveal a preferred substituent orientation. One of these derivatives, the 1-methyl-1,2,3-triazolyl compound (5m) is a more potent synergist of amoxycillin than clavulanic acid, sulbactam or tazobactam.